InflammaSense Selected for ARPA-H CIRCLE Program to Advance Immune Monitoring
News related to:InflammaSense, Inc · 1 min read
LA JOLLA, Calif., Oct. 7, 2026 /CourierPR/ -- InflammaSense, Inc., a pre-revenue medical technology company based in La Jolla, California, has been selected as a performer on a $38 million Advanced Research Projects Agency for Health (ARPA-H) CIRCLE program aimed at advancing real-time immune monitoring in critical care. The company will contribute its VITALx-patch wearable sensor and ARC cascade-endotyping classifier to the effort, which is expected to benefit up to 200 critically ill patients across three clinical sites.
The CIRCLE program, short for Critical Illness Immunological Reprogramming and Control Point Learning Engine, is designed to address the immune dysregulation that drives organ failure in critically ill patients, with sepsis accounting for a significant portion of the roughly 4.6 million Americans who face potentially fatal critical illness each year. The program follows a measure-model-modulate framework, compiling real-time datasets on immune and inflammatory trajectories, building patient-specific computational models, and testing interventions that target immune control points before organ failure progresses.
InflammaSense will deploy its VITALx-patch, a non-invasive wearable sensor, to measure autonomic and inflammatory signatures in up to 200 critically ill patients. The data collected will feed the company's Autonomic Research Core (ARC) cascade-endotyping classifier, which will stratify patients by immune trajectory and support the CIRCLE program's digital-twin modeling of critical illness. This work builds on InflammaSense's core platform, which was built on UC San Diego-owned intellectual property covering neural signal detection of immune responses through cervical autonomic neurography (ANG) measured with ventral cervical or anterior neck magnetoneurography and electroneurography.
The program will be carried out by InflammaSense under a subaward from the University of Vermont, working alongside UVM's Gary An on the ReSCUED effort within CIRCLE. The goal is to advance the understanding and treatment of critical illness, particularly sepsis, by providing clinicians with real-time immune monitoring tools that can help prevent organ failure and save lives.